Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease

Chieko Fujii, S. Harada, N. Ohkoshi, A. Hayashi, K. Yoshizawa, C. Ishizuka, T. Nakamura

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Parkinson's disease (PD) is characterized by major alterations of neurotransmitter activity due to damage of the substantia nigra. Changes in neuropeptide concentration within the basal ganglia may play an important role in the putative dopaminergic-peptidergic interactions associated with the disease. Cholecystokinin (CCK) modulates the release of dopamine in the mesolimbic pathway and affects dopamine-related behavior. We analyzed genetic variations in the CCK gene, in both the coding and promoter region, in order to investigate the role of polymorphism in idiopathic PD. Four polymorphic sites of the CCK gene (-196G/A, -45C/T, 1270C/G, 6662C/T) were found in PD patients and controls. Complete linkage disequilibrium was observed between the -45 locus and the 1270 locus, and also a possible linkage disequilibrium was found between the -45 and -196 loci. A significant difference was found in the distributions of three identified genotypes at the -45 locus between 116 PD patients and 95 age-matched control subjects (χ2 = 7.95, p = 0.018, Bonferroni correction p = 0.054). In addition, a significant difference was obtained amongst the three genotypic groups at the -45 locus when compared between PD patients who experienced hallucinations (n = 23) and those (n = 93) who did not (χ2 = 8.08, p = 0.018, Bonferroni correction; p = 0.126). Our data suggested that mutations at the -45 locus in the promoter region of the CCK gene may influence vulnerability to hallucinations in PD patients treated with L-dopa.

Original languageEnglish
Pages (from-to)394-399
Number of pages6
JournalClinical Genetics
Volume56
Issue number5
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Cholecystokinin
Parkinson Disease
Genes
Hallucinations
Linkage Disequilibrium
Genetic Promoter Regions
Dopamine
Levodopa
Substantia Nigra
Basal Ganglia
Neuropeptides
Neurotransmitter Agents
Genotype
Mutation

Keywords

  • Cholecystokinin gene
  • Drug treatment
  • Hallucination
  • Parkinson's disease
  • Polymorphism

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Fujii, C., Harada, S., Ohkoshi, N., Hayashi, A., Yoshizawa, K., Ishizuka, C., & Nakamura, T. (1999). Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clinical Genetics, 56(5), 394-399.

Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. / Fujii, Chieko; Harada, S.; Ohkoshi, N.; Hayashi, A.; Yoshizawa, K.; Ishizuka, C.; Nakamura, T.

In: Clinical Genetics, Vol. 56, No. 5, 1999, p. 394-399.

Research output: Contribution to journalArticle

Fujii, C, Harada, S, Ohkoshi, N, Hayashi, A, Yoshizawa, K, Ishizuka, C & Nakamura, T 1999, 'Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease', Clinical Genetics, vol. 56, no. 5, pp. 394-399.
Fujii C, Harada S, Ohkoshi N, Hayashi A, Yoshizawa K, Ishizuka C et al. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clinical Genetics. 1999;56(5):394-399.
Fujii, Chieko ; Harada, S. ; Ohkoshi, N. ; Hayashi, A. ; Yoshizawa, K. ; Ishizuka, C. ; Nakamura, T. / Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. In: Clinical Genetics. 1999 ; Vol. 56, No. 5. pp. 394-399.
@article{9b10e78986c341cc9bfefcd6258eca0a,
title = "Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease",
abstract = "Parkinson's disease (PD) is characterized by major alterations of neurotransmitter activity due to damage of the substantia nigra. Changes in neuropeptide concentration within the basal ganglia may play an important role in the putative dopaminergic-peptidergic interactions associated with the disease. Cholecystokinin (CCK) modulates the release of dopamine in the mesolimbic pathway and affects dopamine-related behavior. We analyzed genetic variations in the CCK gene, in both the coding and promoter region, in order to investigate the role of polymorphism in idiopathic PD. Four polymorphic sites of the CCK gene (-196G/A, -45C/T, 1270C/G, 6662C/T) were found in PD patients and controls. Complete linkage disequilibrium was observed between the -45 locus and the 1270 locus, and also a possible linkage disequilibrium was found between the -45 and -196 loci. A significant difference was found in the distributions of three identified genotypes at the -45 locus between 116 PD patients and 95 age-matched control subjects (χ2 = 7.95, p = 0.018, Bonferroni correction p = 0.054). In addition, a significant difference was obtained amongst the three genotypic groups at the -45 locus when compared between PD patients who experienced hallucinations (n = 23) and those (n = 93) who did not (χ2 = 8.08, p = 0.018, Bonferroni correction; p = 0.126). Our data suggested that mutations at the -45 locus in the promoter region of the CCK gene may influence vulnerability to hallucinations in PD patients treated with L-dopa.",
keywords = "Cholecystokinin gene, Drug treatment, Hallucination, Parkinson's disease, Polymorphism",
author = "Chieko Fujii and S. Harada and N. Ohkoshi and A. Hayashi and K. Yoshizawa and C. Ishizuka and T. Nakamura",
year = "1999",
language = "English",
volume = "56",
pages = "394--399",
journal = "Clinical Genetics",
issn = "0009-9163",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease

AU - Fujii, Chieko

AU - Harada, S.

AU - Ohkoshi, N.

AU - Hayashi, A.

AU - Yoshizawa, K.

AU - Ishizuka, C.

AU - Nakamura, T.

PY - 1999

Y1 - 1999

N2 - Parkinson's disease (PD) is characterized by major alterations of neurotransmitter activity due to damage of the substantia nigra. Changes in neuropeptide concentration within the basal ganglia may play an important role in the putative dopaminergic-peptidergic interactions associated with the disease. Cholecystokinin (CCK) modulates the release of dopamine in the mesolimbic pathway and affects dopamine-related behavior. We analyzed genetic variations in the CCK gene, in both the coding and promoter region, in order to investigate the role of polymorphism in idiopathic PD. Four polymorphic sites of the CCK gene (-196G/A, -45C/T, 1270C/G, 6662C/T) were found in PD patients and controls. Complete linkage disequilibrium was observed between the -45 locus and the 1270 locus, and also a possible linkage disequilibrium was found between the -45 and -196 loci. A significant difference was found in the distributions of three identified genotypes at the -45 locus between 116 PD patients and 95 age-matched control subjects (χ2 = 7.95, p = 0.018, Bonferroni correction p = 0.054). In addition, a significant difference was obtained amongst the three genotypic groups at the -45 locus when compared between PD patients who experienced hallucinations (n = 23) and those (n = 93) who did not (χ2 = 8.08, p = 0.018, Bonferroni correction; p = 0.126). Our data suggested that mutations at the -45 locus in the promoter region of the CCK gene may influence vulnerability to hallucinations in PD patients treated with L-dopa.

AB - Parkinson's disease (PD) is characterized by major alterations of neurotransmitter activity due to damage of the substantia nigra. Changes in neuropeptide concentration within the basal ganglia may play an important role in the putative dopaminergic-peptidergic interactions associated with the disease. Cholecystokinin (CCK) modulates the release of dopamine in the mesolimbic pathway and affects dopamine-related behavior. We analyzed genetic variations in the CCK gene, in both the coding and promoter region, in order to investigate the role of polymorphism in idiopathic PD. Four polymorphic sites of the CCK gene (-196G/A, -45C/T, 1270C/G, 6662C/T) were found in PD patients and controls. Complete linkage disequilibrium was observed between the -45 locus and the 1270 locus, and also a possible linkage disequilibrium was found between the -45 and -196 loci. A significant difference was found in the distributions of three identified genotypes at the -45 locus between 116 PD patients and 95 age-matched control subjects (χ2 = 7.95, p = 0.018, Bonferroni correction p = 0.054). In addition, a significant difference was obtained amongst the three genotypic groups at the -45 locus when compared between PD patients who experienced hallucinations (n = 23) and those (n = 93) who did not (χ2 = 8.08, p = 0.018, Bonferroni correction; p = 0.126). Our data suggested that mutations at the -45 locus in the promoter region of the CCK gene may influence vulnerability to hallucinations in PD patients treated with L-dopa.

KW - Cholecystokinin gene

KW - Drug treatment

KW - Hallucination

KW - Parkinson's disease

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=0033402094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033402094&partnerID=8YFLogxK

M3 - Article

C2 - 10668930

AN - SCOPUS:0033402094

VL - 56

SP - 394

EP - 399

JO - Clinical Genetics

JF - Clinical Genetics

SN - 0009-9163

IS - 5

ER -